Background & Aims Hepatocellular carcinoma (HCC) associated macrophages accelerate
tumor progression by growth factor release. Therefore, tumor-associated macrophages …

Sorafenib, a multikinase inhibitor with antiproliferative, antiangiogenic, and proapoptotic
properties, constitutes the only effective first-line drug approved for the treatment of …

BACKGROUND: The phase III Sorafenib Asia–Pacific (AP) trial—conducted in China,
Taiwan and South Korea–confirmed that sorafenib improves overall survival (OS) and is …

Background Sorafenib is the standard treatment for patients with an advanced stage of
hepatocellular carcinoma (HCC). The aims of this study were (i) to evaluate the tolerance …

Angiogenesis and signaling through the RAS/RAF/mitogen-activated protein/extracellular
signal-regulated kinase (ERK) kinase (MEK)/ERK cascade have been reported to play …

Sorafenib is an orally active multikinase inhibitor that targets serine and threonine, and
tyrosine kinases that are involved in tumor‐cell signal transduction and tumor angiogenesis …

Unlike most solid tumors, the incidence and mortality of hepatocellular carcinoma (HCC)
have increased in the United States and Europe in the past decade. Most patients are …

Hepatocellular carcinoma is the fifth most common solid cancer worldwide. Sorafenib, a
small multikinase inhibitor, is the only approved therapy for advanced HCC. The clinical …

Background: Sorafenib is a potent inhibitor against Raf kinase and several receptor tyrosine
kinases that has been approved for the clinical treatment of advanced renal and liver cancer …

Treatment of non small cell lung cancer (NSCLC) and colorectal cancer (CRC) have
substantially changed in the last years with the introduction of epidermal growth factor …